Promoted by SOLTI and developed in scientific collaboration with the Vall d’Hebron Institute of Oncology (VHIO), the SOLTI-1910 RADIOLA study…
Grupo de Cáncer de Mama
The Phase 2 clinical trial PremiÈRe (SOLTI-2104) is the first to evaluate the oral drug elacestrant -either alone or combined…
Results from interim analysis of the international, multicenter, randomized phase III DESTINY-Breast09 study show that the combination of trastuzumab dertuxtecan…
At the recent European Society for Medical Oncology (ESMO) 2025 Congress held in Berlin, Dr. Marta Perachino, a researcher in…
The Paseíco de la Mama solidarity initiative has enabled VHIO’s Breast Cancer Group to carry out numerous research projects over…
Among the 518 women enrolled in the international POSITIVE clinical trial with hormone receptor-positive early breast cancer who temporarily interrupted…
El domingo 22 de octubre se celebró la Pink Run Mir, la carrera a favor de la investigación del cáncer…
